No Data
No Data
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
– Breadth of Alto's pipeline and Precision Psychiatry Platform will be highlighted across twelve posters and presentations at the Society of Biological Psychiatry and American Society of Clinical
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
Recently listed Alto Neuroscience Inc (NYSE:ANRO) released results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with
Alto Neuroscience Schizophrenia Treatment Shows Good Phase 1 Results
Express News | Alto Neuroscience Announces Positive Phase 1 Results For ALTO-101, A Novel PDE4 Inhibitor In Development For Schizophrenia
Express News | Alto Neuroscience Inc - Novel Transdermal Formulation Delivered Significantly Greater Drug Exposure, Fewer Adverse Events Typically Associated With Pde4 Inhibitors
Express News | Alto Neuroscience Inc - Proof-of-Concept Study in Cognitive Impairment Associated With Schizophrenia (Cias) to Be Initiated in First Half of 2024
No Data